Studies on the inhibition of feline EGFR in squamous cell carcinoma:Enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors by Bergkvist, Guraa et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies on the inhibition of feline EGFR in squamous cell
carcinoma
Citation for published version:
Bergkvist, G, Argyle, DJ, Pang, LY, Muirhead, R & Yool, DA 2011, 'Studies on the inhibition of feline EGFR
in squamous cell carcinoma: Enhancement of radiosensitivity and rescue of resistance to small molecule
inhibitors' Cancer Biology & Therapy, vol. 11, no. 11, pp. 927-937. DOI: 10.4161/cbt.11.11.15525
Digital Object Identifier (DOI):
10.4161/cbt.11.11.15525
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Cancer Biology & Therapy
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
www.landesbioscience.com Cancer Biology & Therapy 927
Cancer Biology & Therapy 11:11, 927-937; June 1, 2011; © 2011 Landes Bioscience
 ReseaRCh papeR ReseaRCh papeR
*Correspondence to: Gurå T. Bergkvist; Email: Gura.Bergkvist@ed.ac.uk
Submitted: 09/08/10; Revised: 03/05/11; Accepted: 03/17/11
DOI: 10.4161/cbt.11.11.15525
Introduction
Squamous cell carcinoma (SCC) is common in cats affecting 
the oropharynx, trachea and larynx,1,2 nasal cavity and paranasal 
sinuses3 and skin.4 SCC accounts for up to three quarters of oral 
tumors reported in cats.5 Several treatment options are available 
including surgery,6 radiotherapy,7 chemotherapy8 or a combina-
tion of these,9 but overall survival remains poor.10 Treatment is 
often hampered by the locally aggressive nature of these tumors10 
and the high morbidity that may be seen with treatment.6
Feline oral SCC shares many similarities with human head 
and neck cancer (HNSCC), which is also highly invasive and 
carries a poor prognosis.11 Patients that present with locoregional 
advanced disease have a median survival of 19.1 months with 
chemoradiation treatments.11 Multimodality treatments com-
bining surgery, radiation and chemotherapy are often curative 
but associated with treatment-related morbidity, such as impair-
ment in speech, swallowing and taste.11,12 The etiopathogenesis 
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of HNSCC is considered to be multifactorial, with contribu-
tions from lifestyle and environmental factors such as tobacco 
smoke, genetics and papillomavirus infections.11 Cats share the 
same environments as their owners and may act as sentinels of 
environmental carcinogens.13 Environmental and life-style fac-
tors have also been implicated in the aetiopathogenesis of feline 
oral tumors including grooming behavior, diet, exposure to envi-
ronmental carcinogens including tobacco smoke14,15 and papil-
lomavirus infections.16
Key signaling pathways involved in oncogenesis have also 
been identified in HNSCC. EGFR belongs to the superfamily 
of proteins known as receptor tyrosine kinases. Upon ligand 
binding EGFR dimerizes and activates several downstream path-
ways including the mitogen-activated protein-kinase (MAPK) 
pathway, the phosphatidylinositol-3-kinase (PI3K) pathway and 
the signal transducers and activators of transcription (STAT) 
pathway.17,18 In addition, EGFR activation of the phospholipase 
gamma (PLC-γ) pathway can indirectly activate the PI3K and 
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Acquired resistance to TKI monotherapy commonly develops 
over time,28 so a gefitinib resistant cell line (SCCF1G) was devel-
oped and the tyrosine kinase region was re-sequenced, but no 
mutations were found. Using proliferation assays, the SCCF1G 
cell line showed no significant inhibition of proliferation at the 
5 μM drug dose (Fig. 1A), and was consistently and significantly 
more resistant at concentrations of 1–15 μM gefitinib (p < 0.001 
by two sample t-test). Scratch assays performed on the gefitinib 
resistant cell line showed a comparatively faster migration in 
the resistant cell line (Fig. 1D and E), with the DMSO control 
treated cells having a statistically significant faster basal migra-
tory rate at both time points when compared to the parent cell 
line (p < 0.001, p = 0.024 by two sample t-test for 9 and 24 h 
respectively). Treatment with 10 μM gefitinib produced differ-
ent effects in the cell lines; at 9 h the migratory ability of the 
parent cell line was statistically significantly reduced compared 
to the resistant cell line (p < 0.001 by two sample t-test). The 
gefitinib treated SCCF1 cells had at 9 h migrated 42% of the 
distance of their controls compared to 72% of DMSO control 
treated cells for the resistant cell line. Gefitinib had no effect 
on migration in the resistant cell line at 24 h, with both the 
DMSO treated and the gefitinib treated cells having filled the 
gap completely. In the parent cell line, the gefitinib treated cells 
had migrated just over half the distance of the DMSO control 
treated cells (59% of DMSO treated cells, p = 0.0002 by Mann 
Whitney U test).
siRNA transfections cause reduced cell proliferation and 
EGFR knockdown in SCCF1 cell line. To target the receptor 
using RNAi six siRNAs against the feline Egfr were screened 
using the psiCHECK-2 vector system, and the most effective 
siRNA (siRNA6: sequence antisense strand 5'-3' AGU UCA 
UCA AGG AUU UCC UU) was used in the remaining experi-
ments. SCCF1 cells transfected with siRNA6 exhibited reduced 
proliferation ability compared to mock and scrambled transfected 
cells as well as untreated cells for up to 72 h following transfection 
(Fig. 2A). Transfecting the cells with siRNA6 produced an effect 
equivalent to a 10 μM dose of gefitinib in the SCCF1 cell line 
(Fig. 2B). Real-time PCR revealed a 55% relative reduction in 
Egfr mRNA levels as compared to scrambled control transfected 
SCCF1 cells at 24 h following transfection (Fig. 3A). Protein gel 
blot analysis showed reduction in EGFR protein levels at 72 h fol-
lowing transfection when compared to untreated cells and scram-
bled control transfected cells (Fig. 3B). To investigate the effect 
of Egfr knockdown on downstream signaling pathways of EGFR, 
protein gel blot analysis was performed of markers downstream 
of the EGFR in cells transfected. Reductions in phosphorylated 
Erk1/2 and phosphorylated STAT-3 levels were seen following 
Egfr knockdown (Fig. 3C).
siRNA transfections overcame gefitinib resistance in cell 
line. Targeting of EGFR using siRNAs instead of gefitinib in 
the SCCF1G cell line overcame the resistance to EGFR target-
ing observed when using gefitinib. Transfection of the resistant 
SCCF1G cell line with siRNA6 produced a marked reduction 
in cellular proliferation at 72 h following transfections when 
compared to mock transfected cells. In comparison, gefitinib 
treatment at 5 μM of the resistant cell line caused no significant 
the MAPK pathways and induces nuclear factor kappaB (NFκB) 
upregulation, a pro-survival transcriptional regulator protein.19 
These pathways are important activators of cell proliferation, sur-
vival, angiogenesis and cell migration.17
Overexpression of EGFR has been reported in up to 80%11,20 
of HNSCC tumors and EGFR is a major oncogenic driver in a 
subset of these tumors.11 Developing strategies to target EGFR 
in HNSCC has been the main focus of research in this area and 
recently the first drugs have been approved for clinical use.21 
EGFR has also been reported to be widely expressed in feline 
oral SCC.22,23
RNA interference (RNAi) is a highly specific method of gene 
silencing which utilizes small interfering RNA (siRNA) mole-
cules complementary to the target sequence.24 These bind to gene 
transcripts targeting them for early destruction before translation 
can occur.24 RNA interference techniques are extensively used 
in research but also carry promise for the development of drugs 
capable of targeting specific proteins25,26 including EGFR.27
The aims of this study were to investigate the role of EGFR 
in feline SCCs. Initial results supported the use of small mol-
ecule TKI in these tumors, but resistance to therapy developed. 
An alternative approach to EGFR targeting utilizing RNAi was 
developed, and was shown to rescue acquired TKI resistance 
in the cell line. Furthermore, RNAi used in combination with 
conventional therapies produced an additive effect. These results 
support using feline SCC as a model of HNSCC, an approach 
that could benefit drug development and treatment of both 
tumors.
Results
The feline Egfr tyrosine kinase region shows high degree of 
homology to the canine and human sequence. The sequences 
obtained with the primers designed from the known human, 
canine and murine Egfr sequences had a 100% sequence homol-
ogy with the feline genome according to a basic local alignment 
search tool (BLAST) search and high homology with other 
mammalian Egfr sequences (data not shown). The amino acids 
making up the ATP binding pocket in the human EGFR were 
conserved in the feline EGFR (GenBank accession number 
HQ185236).
Inhibition of EGFR signaling causes reduced cellular prolif-
eration and migration in the SCCF1 cell line. Small molecule 
TKIs like gefitinib bind to the ATP binding pocket and blocks 
phosphorylation.21 Since the ATP binding pocket was preserved 
in the feline cell line, human drugs should be effective against the 
feline receptor. In order to test this, cell proliferation assays were 
performed, and they showed a dose dependent decrease in prolif-
eration rate in response to gefitinib treatment (Fig. 1A). Average 
inhibitory concentration causing 50% reduction in proliferation 
in the SCCF1 cell line was approximately 5 μM (Fig. 1A).
To investigate the effect on inhibition of EGFR signaling on 
cellular migration, scratch assays were performed on cells treated 
with gefitinib (Fig. 1B and C). The SCCF1 cell line showed 
a dose-dependent reduction in migration following gefitinib 
treatment.
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Hairpin expression vectors cause long term knockdown of 
EGFR and reduced proliferating ability and colony forma-
tion in the SCCF1 cell line. Naked siRNA transfections are 
reduction in proliferation when compared to DMSO control 
(p = 0.898, two sample t-test), and 10 μM of gefitinib only had a 
modest effect on proliferation (Fig. 3D).
Figure 1. (a) Cell proliferation assays showing proliferation of sCCF1 and sCCF1G following 72 h of gefitinib treatment at a range of concentrations. 
X axis shows gefitinib concentrations in μM and Y axis shows % of DMsO control treated cells, error bars show standard deviations, *p < 0.001 by two 
sample t-test. (B) In vitro scratch assay of sCCF1 cell line showing effect of eGFR specific tyrosine kinase inhibitor gefitinib on cellular migration. each 
box shows top left DMsO control, top right 1 μM gefitinib, bottom left 5 μM gefitinib, bottom right 10 μM gefitinib at (i) 0, (ii) 12 and (iii) 24 h.  
(C) Graphical representation of the relative migration of the sCCF1 cell line after 24 h of gefitinib treatment compared to DMsO control treated cells. 
The 10 μM gefitinib dose produced a 23% reduction in gap width after 24 h compared with the 100% reduction observed in DMsO treated cells  
(*p < 0.001 by one-way aNOVa). (D) In vitro scratch assay comparing migratory ability of the two cell lines. Top row shows 0 h, middle row 9 h and 
bottom row 24 h following gefitinib treatment. (e) Graphical representation of relative migration of cell lines shown in (D). The basal migratory rate of 
the cell lines differed, illustrated by the DMsO control treated cells. after 9 h, the DMsO control treated sCCF1 had closed the gap created for the assay 
by less than half while the sCCF1G cell line had reduced the width with over two thirds (*p < 0.001, two sample t-test). The 10 μM dose of gefitinib had 
different effect on the cell lines. at 9 h the resistant cell line had reduced the gap width with approximately half compared to only a fifth in the parent 
cell line (**p < 0.001, two sample t-test) and at 24 h the resistant cell line had migrated and filled the gap completely while the parent cell line had only 
migrated approximately half way across the gap (***p = 0.0002 by Mann Whitney U test).
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statistical significance (p = 0.06 by Mann Whitney 
U test).
Cell proliferation assays performed on the 
cell line after 20 days of antibiotic selection (Fig. 
4D) showed a statistically significant difference 
between the cell proliferation rates at all three 
time points. The effect on proliferation after 20 
days was less pronounced compared to the effect 
observed in transiently transfected cells (Fig. 2A).
Radiation and EGFR knockdown show an 
additive effect in the SCCF1 cell line. To inves-
tigate the effect of Egfr targeting in combination 
with conventional therapies a radiosensitivity 
assay was performed. Ten days after radiation 
colony formation assays showed a dose depen-
dent reduction in colony formation ability in 
the irradiated cells which was enhanced in the 
siRNA6 but not the scrambled transfected or 
gefitinib treated cells (Fig. 5A and B). An addi-
tive effect was observed when siRNA6 transfec-
tions were combined with irradiation according 
to the Bliss additivism model (Fig. 5C).
Discussion
This study demonstrated that the tyrosine kinase 
region of the feline Egfr gene has a high degree 
of homology with the human gene, including 
a preserved ATP binding pocket. In addition, 
a commercially available monoclonal antibody 
produced against the EGF binding region of 
the human protein (EGFR Ab-12, Thermo-
Scientific) also binds specifically to feline EGFR 
epitopes showing species cross reactivity (protein 
gel blot analysis Fig. 4B). Although these results 
represent only one cell line, and further studies 
should be performed investigating a panel of 
feline oral SCC cell lines and preferably compar-
ing them to human HNSCC cell lines, these findings do support 
using feline oral SCC as a natural model for HNSCC as specific 
EGFR targeting strategies used in man are likely to also target 
feline EGFR. Specific therapeutics targeting EGFR, like TKIs 
and monoclonal antibodies (mAbs), have been approved for clin-
ical use in a range of solid tumors including HNSCC.17 TKIs 
block the ATP binding pocket of the tyrosine kinase domain 
of EGFR preventing activation of downstream targets,21 while 
mAbs block the ligand binding region of the receptor prevent-
ing activation and target it for antibody dependent cell-mediated 
cytotoxicity.17 This study aimed to test currently available human 
EGFR targeting strategies in the feline model, and a TKI was 
chosen as mAbs used in human medicine are either humanised or 
chimeric antibodies. If used in veterinary species they are likely to 
cause anti-human antibody responses similar to the human anti-
mouse antibody responses seen in man to murine antibodies.29,30
In this study gefitinib effectively reduced cellular migration 
and proliferation in the feline SCC cell line, but at the relatively 
typically transient in nature, with observed effects lasting up 
to one week.24 To investigate if longer term knockdown of the 
receptor could be achieved, the siRNA sequence was cloned into 
a hairpin expression vector. Transfection efficiencies achieved 
with the hairpin transfection vectors were lower than what was 
achieved with the naked siRNA transfections (53 vs. 69% for 
vector and siRNA transfections respectively, data not shown).
Real Time PCR analysis (Fig. 4A) showed variable reduction 
in EGFR mRNA levels in EGFR transfected cells compared to 
scrambled transfected cells with an average reduction of 35% (SD 
18%, range 10–53%). Similarly, protein gel blot analysis (Fig. 
4B) of cell lysates produced 20 days after transfection showed 
variable reduction in EGFR protein levels when compared to 
scrambled controls.
Colony formation assays were performed during antibiotic 
selection (Fig. 4C) and the cell lines ability to form colonies were 
reduced on average with 45% compared to scrambled control trans-
fected cells. This difference, however, only showed a trend towards 
Figure 2. (a) Cell proliferation assay showing proliferation of sCCF1 cells up to 72 h post 
siRNa6 transfections compared to untreated sCCF1 cells, mock and scrambled control 
transfected cells, *p < 0.0001, at 48 and 72 h by one-way aNOVa. (B) Cell proliferation assay 
comparing the effect on proliferation of siRNa6 transfection and gefitinib at 24, 48 and 72 h. 
a single siRNa6 transfection produced an equivalent effect to a 10 μM dose of gefitinib.
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acquired resistance in the cell line prompted the search for an 
alternative approach to EGFR targeting.
The cell line in this study developed resistance to gefitinib 
treatment following chronic exposure. In man, the T790M muta-
tion in the tyrosine kinase domain has been associated with the 
development of resistance to gefitinib in NSCLC.35 It results in a 
substitution of methionine for threonine in the ATP binding site 
increasing the receptor affinity for ATP.35 In this study, however, 
high dose rate of 10 μM. An in vitro dose of gefitinib of 1 μM 
is equivalent to a clinical dose of 250 mg per day used in non- 
small-cell lung cancer (NSCLC).31 In NSCLC in vitro studies 
doses above 2 μM of gefitinib would class the cell line as insensi-
tive to the drug.31 Early studies on HNSCC cell lines used much 
higher doses than this32 while more recent studies all have used 
doses below 2 μM gefitinib.33,34 The relative insensitivity of the 
cell line to gefitinib in combination with the development of 
Figure 3. (a) Diagram showing real time pCR result of Egfr mRNa levels in sCCF1 cells transfected with siRNa6 expressed as percentage of 
scrambled control levels. Results shown are an average of triplicate transfections and each transfection was run in three technical replicates for the 
real time pCR. similar results were obtained in separate experiments. (B) protein gel blot showing reduction in eGFR protein levels 72 h post siRNa 
transfection of sCCF1 cell line. Lysates from mock transfected, M, and scrambled control transfected cells, s, are show next to lysates from sCCF1 
cells transfected with siRNa6 against the feline Egfr in triplicates, e, while lower band show β-actin levels for loading control. (C) protein gel blot 
showing levels of phosphorylated downstream targets of eGFR in siRNa6 transfected sCCF1 cells, e, compared to scrambled control transfected 
cells, s. a reduction was seen in phosphorylated sTaT-3 and erk1/2 levels in the eGFR transfected cells. Total erk1/2, total sTaT-3 and β-actin levels 
are shown for loading control. (D) Mock transfections and DMsO treatments of both cell lines had minimal effect on proliferation, while gefitinib 
treatment and Egfr siRNa6 transfections caused marked effects on the sCCF1 cell line. The sCCF1G cell line exhibited resistance to doses of gefitinib 
of up to 10 μM while siRNa transfections against the feline eGFR still caused reduction in proliferation in the cell line. Bars show standard devia-
tions, *p < 0.001, **p < 0.001 compared to DMsO control and mock transfected respectively by two sample t-test, #p = 0.005 compared to mock 
transfected by Mann Whitney U test.
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their relative efficiencies in the nucleus are unknown. siRNAs 
exert their effect mainly in the cytoplasm of cells,37 but if effi-
cient will reduce nuclear as well as membranous and cytoplasmic 
receptor levels. Increased expression of receptor ligands36 would 
have limited effect on transfected cells as the receptor levels 
would be markedly reduced. If the cells upregulated other mem-
bers of the receptor family like for example ErbB3,38 the siRNA 
would not be expected to be effective. An alternative resistance 
pathway relies on transactivation of EGFR by the cytosolic tyro-
sine kinase Src.39 siRNAs targeting Egfr would still be effective 
in this scenario as the reduction in receptor protein levels would 
counteract the increased phosphorylation. Likewise, if the recep-
tor ubiquitination and degradation pathways were dysregulated,40 
siRNAs targeting Egfr would still be effective. Regardless of the 
similar mechanisms were not responsible for the development of 
resistance in the cell line as no mutations were found in the ATP 
binding pocket of the receptor when the region was re-sequenced 
in the resistant cell line. This is in accordance with reports in the 
literature on the development of resistance to TKIs in HNSCC in 
which tyrosine kinase mutations of Egfr are rare events.28 Cancer 
cells become resistant to EGFR targeted therapies through sev-
eral mechanisms. The nature of the gefitinib resistance in the 
SCCF1G cell line in this study is not known, but some of the 
previously reported mechanisms of resistance could be consistent 
with an apparent resistance to tyrosine kinase inhibition but not 
to siRNA. Nuclear translocation has been implicated in resis-
tance to the monoclonal antibody cetuximab.36 Although it has 
been suggested that small molecule TKIs affect nuclear EGFR,36 
Figure 4. (a) Real time pCR results showing Egfr mRNa levels post 3.1pSilencerTM neo Kit transfections of sCCF1 cell line after culturing cell line for 20 
days in selective media. each bar is an average of three technical replicates run from separate transfection experiments. (B) protein gel blot showing 
variable reduction in eGFR protein levels in two lysates from different pSilencer neo Kit transfections. MDa-MB (lane 1) contains lysate from the MDa-
MB-468 cell line (MD anderson Cancer Center, TX), a human breast cancer cell line that overexpresses eGFR. It was used as positive control to validate 
the antibody for the use on feline protein lysates. Lanes 2–5 contain lysates from sCCF1 cell line: eGFR, transfected with vector expressing shRNa 
against eGFR; scram, transfected with vector with scrambled control sequence; sCCF1, untransfected cells. protein loaded: 30 μg MDa-MB, 60 μg 
remaining samples. (C) Colony formation assay performed during 20 days of G418 selection post hairpin expression vector transfection. a 45% reduc-
tion in colony formation ability was seen in the eGFR transfected cells when compared to scrambled control transfected cells. The histogram shows 
average number of colonies counted with error bars showing standard deviations. Bars is average of eight (eGFR) and nine (scrambled) 10 cm plates 
for each sample and represents transfections performed in triplicate. The difference showed a trend towards statistical significance (p = 0.06 by Mann 
Whitney U test). (D) Cell proliferation assay showing sCCF1 cell lines proliferating ability after 20 days of selection with G418 containing media. eGFR 
transfected cells showed a statistically significant lower proliferation rate when compared to scrambled transfected cells at 24, 48 and 72 h (*p = 0.001, 
p = 0.003 and p < 0.001 respectively, two sample t-test). each point show an average absorbance value of four wells with the background subtracted, 
bars show standard deviation. similar results were obtained in two separate experiments.
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PI3K pathway with six separate phosphorylation sites for the p85 
subunit of PI3K.42 EGFR targeting may be less likely to cause a 
major reduction in PI3K pathway activation if ErbB3 receptor 
remains active. The clinical responses to EGFR targeting thera-
pies in human trials have so far been modest11 and this may be 
because tumors have an intrinsic resistance to EGFR-targeted 
mechanism used by the cells in this study, 
the net effect was that resistance to gefi-
tinib could be overcome by using RNAi 
to target Egfr. This study illustrated how 
the resistant cancer cells were still depen-
dent on EGFR for proliferation, despite 
acquiring resistance to an EGFR target-
ing drug.
This study demonstrated that Egfr 
siRNA effectively reduced both Egfr 
transcripts and EGFR protein in the 
SCCF1 cell line. RNAi was used in this 
study as it is a highly selective method of 
evaluating the effect of gene silencing of a 
target gene.24 Silencing the feline Egfr in 
the cell line had a profound effect on cell 
proliferation and colony formation abil-
ity and this effect could be sustained over 
time. This demonstrates that EGFR is an 
important oncogenic driver in this model 
of feline oral SCC and that targeting 
EGFR in feline oral SCC has potential as 
a therapeutic strategy.
This study also investigated the 
effect of EGFR targeting on the path-
ways downstream of the receptor and 
demonstrated that some of the pathways 
involved in cell proliferation and angio-
genesis including MAPK and STAT-3 
were downregulated. A marked reduc-
tion in proliferation was seen in the cells 
following EGFR knockdown in this study, which is consistent 
with a reduction in phosphorylation in these two pathways.17,31 
Although EGFR has been shown to directly activate the PI3K 
pathway mediated by growth factor receptor binding 2 (Grb-2)-
associated binding protein 1 (Gab1),41 ErbB3, a closely related 
member of the Egfr gene family, is the major activator of the 
Figure 5. (a) Graphs show results of colony 
formation assays post radiation and eGFR 
knockdown in sCCF1 cell line ten days 
following radiation. Cells transfected with 
siRNa6 showed statistically significant re-
duction in colony formation ability as com-
pared to untreated and scrambled control 
transfected cells at 0, 0.5 and 3 Gy radiation 
doses (*p = 0.007, p = 0.022 and p = 0.028 re-
spectively, one-way aNOVa). (B) histogram 
showing colony formation assay following 
eGFR targeting by either siRNa6 or gefitinib 
at 5 μM and radiation at 0, 0.5 and 3 Gy. 
Gefitinib at a dose of 5 μM showed no effect 
on colony formation ability compared to 
siRNa6 transfection. (C) Graph showing ad-
ditive effect of combining siRNa6 transfec-
tion and radiation. The predicted graph 
gives the ebliss values for radiation and eGFR 
targeting causing an additive effect accord-
ing to the Bliss additivism model.
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of EGFR showed additive rather than synergistic effects when 
cetuximab was combined with radiation,44 which is similar to 
the findings in this study. EGFR-targeted therapy may be of 
clinical value in augmenting radiotherapy in feline oral SCC but 
tumors expressing higher EGFR levels may be more sensitive to 
combined treatment.
In this study we utilized RNAi for EGFR targeting, and it 
proved to efficiently reduce the target protein levels and cell pro-
liferation in the cell line. RNAi is a promising technique that has 
wide applications in research but with emerging uses in therapeu-
tics.24 RNA interference may prove to be a powerful tool for the 
new generation of targeting therapies where acquired resistance 
to drugs has developed over time. In a recent study, transfection 
of cetuximab resistant HNSCC cell lines with siRNA against 
EGFR reversed the acquired resistance in the cell lines.38 This 
is similar to the findings in this study, were transfection of the 
gefitinib resistant cell line caused similar reduction in cell prolif-
eration as in the non-resistant parent cell line SCCF1. The major 
obstacle to wider clinical use of RNAi based drugs is the lack of 
a good in vivo delivery system24 but this area is advancing and 
the first siRNA-based clinical trial using a nanoparticle deliv-
ery system has been reported.25 If a suitable delivery vector can 
be found, RNAi may become an attractive option for achieving 
EGFR-targeted therapy.
Feline SCCs are naturally occurring tumors that have devel-
oped in pet animals which possess an intact immune system and 
which share their environment with humans. The aetiopathogen-
esis of the disease in cats is not fully characterised, but environ-
mental factors similar to those in man have been postulated as 
risk factors.46 Evaluating drug strategies in naturally occurring 
disease in pets may help bridge the gap between in vitro research 
and clinical application in man.47 This study supports the use 
of feline SCC as a model for HNSCC, an approach that could 
potentially benefit both felines and humans alike. During the 
development of a TKI against KIT (SU11654, toceranib)48 the 
human field benefited greatly from the canine studies,47 and the 
development of acquired resistance to single-agent TKIs in dogs 
with mast cell tumors is of particular interest.47 Further studies 
in cats with SCCs using EGFR targeting siRNA based therapies 
in combination with radiotherapy would potentially advance the 
treatment of the disease in both species.
Materials and Methods
Cell culture. Cell culture reagents were obtained from Gibco® 
Invitrogen unless otherwise specified. The SCCF1 cell line49 is a 
previously characterised feline cell line derived from a laryngeal 
squamous cell carcinoma. The cells were grown in William’s E 
Medium with GlutaMAX supplemented with 10% FBS, 0.05 
mg/ml Gentamicin and 10 ng/ml EGF. For post-transfection 
selection of cells 0.4 mg/ml Geneticin (G418) was added to the 
medium.
For the siRNA screening protocol, the 293FT cell line 
(Invitrogen) was used. The 293FT cell line was grown in 
DMEM supplemented with 10% FBS, 0.1 M Non-Essential 
Amino Acids, 6 mM L-glutamine, 1 mM Sodium Pyruvate, 1% 
therapy.11,36 These problems may be overcome by using combi-
nation therapies that target these alternative resistance pathways 
and by improved selection of patients that are more likely to 
respond to EGFR targeting.11
Part of effective clinical application of Egfr RNAi is likely 
to include inducing prolonged EGFR inhibition to have a sus-
tained effect. Direct transfection of siRNA molecules produces 
only transient inhibition of Egfr gene expression as siRNA mol-
ecules become depleted or destroyed.24 To evaluate the effect 
of sustained Egfr gene knockdown, a plasmid that expressed 
short-hairpin RNA molecules was developed. This study demon-
strated that a hairpin expression vector can be effectively taken 
up by cells and lead to sustained production of shRNAs. The 
short hairpin expression vector transfection efficiency was lower 
than the naked siRNA transfection efficiency. To counter this 
effect, antibiotic selection was used to enrich for cells incorporat-
ing the expression vector. Despite selection, the efficacy of gene 
knockdown and the variability between transfection replicates 
were greater when using hairpin expression vectors compared to 
naked siRNAs. Possible explanations include that some clones 
may have developed resistance to the shRNAs by acquiring muta-
tions rendering them insensitive to interference by the shRNA. 
Alternatively, as experiments have shown, between 1–10% of vec-
tors integrated into the genome during stable transfections are 
not intact.43 These clones may have acquired the antibiotic resis-
tance gene without acquiring functionally intact shRNA expres-
sion. Considering that EGFR knockdown is deleterious to cell 
proliferation, these clones would have a growth advantage over 
the cells expressing shRNAs against the feline Egfr.
In HNSCC the role of chemoradiation is well established,11 
and a monoclonal antibody targeting the EGFR, cetuximab, has 
been given FDA approval for use in combination with radiother-
apy for HNSCC.11,17 Combination of EGFR targeted therapy 
and radiotherapy for management of feline oral squamous cell 
carcinoma is attractive as EGFR-mediated therapy may be able 
to augment the efficacy of radiotherapy, an established treatment 
option.7 Combined therapy with radiation and EGFR targeting 
produced an additive effect similar to that observed in human 
HNSCC cell lines32,44 and xenograft models.32 A study investi-
gating the effect of cetuximab in combination with cisplatin and 
irradiation in HNSCC cell lines reported an additive effect in 
five cell lines while two cancer cell lines exhibited a synergistic 
effect.44 When comparing EGFR basal and phosphorylated lev-
els between the cell lines exhibiting additive versus synergistic 
effects, they found that the cell line that exhibited synergy had a 
much higher basal level of EGFR and that the receptor became 
phosphorylated upon irradiation.44 This supports the theory 
that overexpressing EGFR cell lines are more likely to respond to 
EGFR targeting therapy.45 In these cell lines combination treat-
ments are thought to act synergistically because the cell lines 
utilize EGFR pathways like the PI3K and MAPK pathways to 
counteract the effect of radiation.19 When these pathways are 
blocked, the cells become more sensitive to radiation.19
The SCCF1 cell line had a relatively low basal level of EGFR 
when compared to known EGFR overexpressing human cancer 
cell line MD-MBA-468. HNSCC cell lines with low basal levels 
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In vitro scratch assay. Cells were grown to confluency in six 
well plates and a scratch was created with a one ml pipette tip in 
the monolayer as previously described in reference 50. The gap 
width was measured at ten points for each photograph and the 
mean was expressed as percentage of gap width at 0 h and com-
pared between treatment groups.
siRNA design, construction and screening. Six siRNAs 
against the feline sequence were designed using the Ambion 
siRNA finder (www.ambion.com/techlib/misc/siRNA_finder.
html). They were produced using Silencer® siRNA Construction 
Kit (Ambion) following manufacturer’s recommendations and 
screened using the psiCHECK-2 vector system (Promega). The 
psiCHECKTM-2 vector has two reporter genes. The Renilla pri-
mary reporter gene was fused with the directionally cloned feline 
Egfr gene sequence. This allowed for monitoring of target gene 
expression following transfections with the different siRNAs. 
The Firefly secondary reporter gene was used to normalise the 
Renilla readings to correct for variations due to different trans-
fection efficiency between samples. Following electroporation, 
the luminescence was read on a plate reader (1420 Multilabel 
Counter Victor3TM, Perkin Elmer, Germany) using the Dual-
GloTM Luciferase System (Promega) following manufacturer’s 
protocol.
Vector cloning. DNA oligonucleotide templates (top strand 
5'-GAT CCG GAA ATC CTT GAT GAA GCT TTC AAG 
AGA AGC TTC ATC AAG GAT TTC CTT TTT TGG AAA-
3' and bottom strand 5'-AGC TTT TCC AAA AAA GGA AAT 
CCT TGA TGA AGC TTC TCT TGA AAG CTT CAT CAA 
GGA TTT CCG-3') was ligated into the BamH I or Hind III 
restriction sites of the 3.1pSilencerTM neo Kit (Ambion) and the 
500 base pairs sequence produced by primer pair A with the 
sequences of restriction enzyme sites Not I and Xho I added 
was ligated into the psiCHECK-2 vector (Promega) by T4 DNA 
ligase (Bioline). The ligation reactions were used directly in One 
Shot Chemically Competent E. coli (Invitrogen) transformation 
reactions. Colonies were selected and expanded overnight before 
performing plasmid purifications using QIAfilter Plasmid Midi 
Kits (Qiagen) according to manufacturer’s protocol. The vectors 
were sequenced to ensure the correct sequences had inserted.
Transfections. For the siRNA screening, transfections of the 
293FT cell line by electroporation were performed using the 
Nucleofector® 96-well shuttle (Amaxa, Lonza, Switzerland) and 
Cell Line 96-well Nucleofector® Solution SF Kit (Amaxa) fol-
lowing manufacturer’s protocol. In brief, cells were seeded at 2 x 
105 cell per well into a NucleocuvetteTM 96-well plate and 1 μg 
psiCHECKTM-2 vector was co-transfected with 250 nM siRNA 
per well in triplicate using program DS-150. Cells were cultured 
for 24 h before luminescence were assessed using the Dual-GloTM 
Luciferase System (Promega).
The SCCF1 and SCCF1G cell lines were transfected with 
50 nM RNA or with 4 μg DNA using LipofectamineTM 2000 
(Invitrogen) following manufacturer’s protocol. Cells were trans-
fected with siRNA against the feline Egfr, scrambled sequence 
Silencer® Negative Control #1 siRNA (Ambion) or with pSilen-
cerTM neo Kit hairpin expression vectors containing the sequence 
directed against the feline Egfr or a scrambled control sequence. 
Penicillin-Streptomycin and 0.5 mg/ml G418. During transfec-
tions, cells were grown in DMEM media as above without anti-
biotics and, immediately following electroporation, cells were 
resuspended in RPMI media containing 10% FBS before plated 
in normal DMEM growth media with antibiotics.
Buffers and reagents. Reagents were obtained from Sigma 
Aldrich unless otherwise specified. The following buffers were 
used: Urea lysis buffer: 7 M Urea, 0.1% DTT, 0.05% v/w Triton 
X-100, 25 mM NaCl and 20 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES) (pH 7.5). Tris-buffered saline 
Tween-20 (TBST): 20 mM Tris-HCl, 0.15 M NaCl and 0.1% 
Tween-20. TBST blocking buffer: 5% Bovine Serum Albumin 
(BSA) in TBST. Phosphate-buffered saline (Gibco) Tween-20 
(PBST): 0.01 M Phosphate, 0.154 M NaCl and 0.1% Tween-20, 
pH 7.4. PBST blocking buffer: 5% Skimmed Milk (Oxoid) in 
PBST. 2x Laemmli Sample Buffer: 120 mM Tris-HCl pH 6.8, 
4% (w/v) sodium dodecyl sulphate (SDS), 20% (v/v) glycerol, 
200 mM DTT, 0.04% (w/v) bromophenol blue.
Cloning and sequencing of feline EGFR tyrosine kinase 
region. Total RNA was isolated using RNeasy Mini Kit 
(Qiagen). First strand cDNA was synthesised from 2 μg RNA 
using Qiagen Omniscript® Reverse Transcriptase Kit and 
OligoT primers (Qiagen). Three primer sets were designed to 
span the putative tyrosine kinase region of the feline Egfr gene 
using areas with a high degree of homology between the human, 
murine and canine published sequences (www.ncbi.nlm.nih.
gov and www.ensembl.org/index.html) (5' to 3' primer pair A: 
for GGA GAA GCT CCC AAC CAG GCT, rev GAT AGG 
CAC TTT GCC TCC TTC, B: for GAA TAT CAC CTG CAC 
AGG AC, rev GCC ATC ACG TAA GCT TCA TC and C for 
TGC GAA GGG CAT GAA CTA C, rev ACT CAT CGG CAT 
CTA CGA C). All DNA oligonucleotides were purchased from 
Eurofins MWG Operon and PCR reactions were performed 
using HotStar® DNA polymerase kit (Qiagen) on iCycler ther-
mal cycler (BioRad) using the following conditions: one cycle 
of initial denaturation at 95°C for 15 min followed by 25 cycles 
of one min each at 94°C (denaturation), 52°C (annealing) and 
72°C (extension) before a final extension step of 72°C for 10 min.
Samples were sequenced in both directions at The Gene Pool 
(The University of Edinburgh, Edinburgh, UK) using primer 
pairs A, B & C, and were then checked against the feline genome 
using the Basic Local Alignment Search Tool (BLAST) nucleo-
tide search (www.ncbi.nlm.nih.gov/genome/seq/BlastGen/
BlastGen.cgi?taxid= 9685).
Gefitinib treatment of cell line. Gefitinib (Tocris Bioscience 
184475-35-2) was used at a range of concentrations from 
1 nM to 20 μM. To produce a gefitinib resistant cell line 
SCCF1G, the SCCF1 cell line was maintained in its normal 
media supplemented with 5 μM of gefitinib for 5 months.
Cell proliferation assays. Cells were seeded into 96 well plates 
at 1,500–3,000 cells per well and allowed to attach overnight 
before treatment. Cellular proliferation was measured using 
the CellTiter 96® AQ
ueous
 One Solution Cell Proliferation Assay 
(Promega) according to manufacturer’s protocol and absorbance 
at 490 nm was determined on a plate reader (Perkin Elmer 1420 
Multilabel Counter Victor3TM).
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(radiosensitivity assay) or 24 h following shRNA expression 
plasmid transfection into G418 containing selective media. The 
media was changed and the plates were checked for colony for-
mation twice weekly. After 10–20 days the colonies were fixed in 
cold methanol, stained by adding 10% Giemsa stain and manu-
ally counted.
Radiosensitivity assay. SCCF1 cells were transfected or 
treated with 5 μM gefitinib in six-well plates and incubated 
for 24 h before being irradiated. All cells were irradiated in cul-
ture medium using a Faxitron® cabinet X-ray system 43855D 
(Faxitron X-ray Corporation) at a central dose rate of 2 Gray 
(Gy)/min. All irradiation was given as a single fraction at room 
temperature. Cells were trypsinated and counted 24 h after 
transfections and 300 cells were seeded in triplicate into ten-
cm plates and irradiated in suspension at 0, 0.5 and 3 Gy prior 
to performing CFAs as previously described.
Statistical analyses. All experiments with the exception of the 
radiosensitivity assay were repeated at least on two separate occa-
sions with similar results. All quantitative analysis is based on a 
minimum of three replicates for 6-well plates and ten cm plates 
or a minimum of four wells for 96-well plates for each separate 
experiment. One-way ANOVA was used to compare differences 
between more than two samples. Two sample t-tests or the non-
parametric equivalent Mann-Whitney U test were used to com-
pare differences between two samples. Results were considered 
significant when p < 0.05. All statistical analysis was performed 
using Minitab® 15 Statistical software (Minitab Ltd.) and all 
graphs were generated using Microsoft® Office Excel 2010 soft-
ware. To assess the effect of combining radiation with EGFR 
knockdown in the SCCF1 cell line the Bliss additivism model 
was used as previously described in reference 52.
Acknowledgments
This work was generously supported by a grant from the Petplan 
Charitable Trust. The authors would also like to thank Prof. 
T.J. Rosol at the College of Veterinary Medicine, Ohio State 
University, OH, for provision of the feline cell line SCCF1.
Cells transfected with the hairpin expression vectors were tryp-
sinated and counted 24 h following transfection, seeded at 3 x 
105 cells per well into six-well plates before adding selective G418 
containing media for 20 days.
Real time PCR. Total RNA was isolated using RNeasy Mini 
Kit (Qiagen). First strand cDNA was synthesised from 1.0 μg 
RNA using Roche Transcriptor High Fidelity cDNA Synthesis 
Kit and random hexamers (Roche). Primers and FAM labeled 
probes for feline EGFR and feline β-actin were designed using 
Roche Universal Probe Library (www.roche-applied-science.
com/sis/rtpcr/upl/index.jsp). Real Time PCR reactions were set 
up using Roche LightCycler® 480 Probes Master kit according 
to manufacturer’s protocol and 2 μl of cDNA synthesis reaction 
diluted 1:10. The thermal conditions were one pre-incubation 
step at 95°C for ten min followed by 45 cycles consisting of 10 s 
of denaturing at 95°C, 30 s of annealing at 54°C and 1 s of exten-
sion at 72°C before cooling. VIC labeled probes and primers for 
human 18S rRNA (Applied Biosystems) was used as a reference 
gene. Relative mRNA expressions were determined according to 
the Pfaffl method.51
Protein gel blot analysis. Cells were lysed in urea lysis buffer 
72 h after transfections, cleared by centrifugation and quanti-
fied using a standard Bradford absorbance assay. The proteins 
were resolved on 8% SDS-polyacrylamide gel electrophore-
sis, transferred onto nitrocellulose membranes, blocked and 
incubated with primary antibodies overnight. The membranes 
were then incubated with HRP-conjugated secondary antibod-
ies (Dako) diluted 1:2,000 and developed using Immun-StarTM 
westernCTM Kit (BioRad). The antibodies used were EGFR 
(MS-400-P0, Thermo-Scientific), phospho-MAPK/Erk1/2 
(D13.14.4E, Cell Signalling Technologies), total MAPK/
Erk1/2 (137F5, Cell Signalling Technologies), phospho-STAT-3 
(SC-81523, Santa Cruz), total STAT-3 (SC-7179, Santa Cruz) 
and β-actin (ab6276, abcam).
Colony formation assays (CFAs). Cells were seeded at a den-
sity of 300–500 cells per 10 cm plate 24 h following transfec-
tion with naked siRNA or gefitinib treatment into normal media 
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